Polymorphism in the P-glycoprotein drug transporter MDR1 gene
- 1 May 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 13 (5), 259-263
- https://doi.org/10.1097/00008571-200305000-00004
Abstract
P-glycoprotein is a membrane protein encoded by theMDR1gene, which demonstrates functional polymorphism. It is present in endothelial cells of the blood-brain barrier, thus limiting accumulation of its substrates in the central nervous system. Many epidemiological studies suggest an association between pesticides, which are substrates for P-glycoprotein, and Parkinson's disease. It was hypothesized that polymorphism of theMDR1gene could modulate interindividual susceptibility for the disease in subjects exposed to pesticides. In a pilot case-control study involving 107 Parkinson's disease patients (30 early onset and 77 late onset patients; 59 exposed to pesticides and 48 non-exposed) and 103 controls, C3435T polymorphism of the gene was analysed. No statistically significant correlation betweenMDR1gene polymorphism and Parkinson's disease was found. The 3435TT genotype was noted more frequently, but not significantly, in patients with early onset compared to late onset disease (23.3% versus 10.4%, respectively). A significant association between patients with parkinsonism exposed to pesticides and C3435T polymorphism of theMDR1gene was found. Comparing the exposed and non-exposed patients, a statistically higher frequency of heterozygous subjects was observed (72.9% versus 47.9%, respectively). This genotype was associated with a significant, almost three-fold increased risk of disease. Similarly, a higher frequency of 3435TT subjects was revealed in exposed subjects (15.5%) compared to non-exposed patients (12.5%). In exposed versus non-exposed subjects, patients carrying at least one 3435T allele (i.e. homozygous and heterozygous) had a significant, five-fold higher risk of Parkinson's disease. Thus, it appears that mutation of the MDR1 gene predisposes to damaging effects of pesticides, and possibly other toxic xenobiotics transported by P-glycoprotein, leading to Parkinson's disease.Keywords
This publication has 16 references indexed in Scilit:
- N-acetyltransferase 2 polymorphism in sporadic Parkinson's disease in a Polish population.European Journal of Clinical Pharmacology, 2002
- Variability and validity of polymorphism association studies in Parkinson’s diseaseNeurology, 2000
- Role of P-Glycoprotein in Drug DispositionTherapeutic Drug Monitoring, 2000
- Candidate genes and Parkinson’s diseaseNeurology, 1999
- Case-control study of interactions between genetic and environmental factors in Parkinson's diseaseThe Lancet, 1998
- The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural livingNeurology, 1998
- Environmental risk factors and Parkinson's diseaseNeurology, 1997
- P-Glycoprotein Deficiency in a Subpopulation of CF-1 Mice Enhances Avermectin-Induced NeurotoxicityToxicology and Applied Pharmacology, 1997
- P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.Journal of Clinical Investigation, 1996
- Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugsCell, 1994